Floatz logo

Rituximab

Hematopoietic And Lymphoid System Neoplasm

Explore 134 assets in Hematopoietic And Lymphoid System Neoplasm →
Floatz Rating
B60/100
Confidence
Indicative
v0.2
Sponsor
Indapta Therapeutics, INC.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06119685CT.gov
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
—Recruiting———
NCT04138875CT.gov
A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)
—Withdrawn———
NCT03878524CT.gov
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
—Terminated———
NCT02663518CT.gov
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
—Terminated———
NCT02367196CT.gov
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
—Completed———
NCT01010217CT.gov
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
—Completed———
NCT00788684CT.gov
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Hematopoietic And Lymphoid System Neoplasm

AssetSponsorPhaseRating
Rituximab (this asset)Indapta Therapeutics, INC.P2B · 60
AdriamycinOHSU Knight Cancer InstituteP4BBB
TeclistamabJanssen Pharmaceutical K.K.P2BB
DexasoneCity of Hope Medical CenterP3BB
BortezomibOHSU Knight Cancer InstituteP4BB
CyclophosphamideNational Cancer Institute (NCI)P3BB
Allogeneic, Ex Vivo Expanded, Umbilical Cord Blood-Derived Hematopoietic Cd133+ Progenitor Cells- Cultured Fraction (Cf)Gamida Cell ltdP3BB
EtoposideCiusss de L'Est de l'Île de MontréalP2BB
PembrolizumabVividion Therapeutics, Inc.P3BB

+42 more in the Hematopoietic And Lymphoid System Neoplasm cohort

Other indications for Rituximab

IndicationSponsorPhaseRating
Lymphoblastic Lymphoma—P4BBB · 75
Grade III Lymphomatoid Granulomatosis—P2BBB · 74
Testicular Lymphoma—P2BBB · 74

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Rituximab in Hematopoietic And Lymphoid System Neoplasm. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-hematopoietic-and-lymphoid-system-neoplasm

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →